Has serputinib/serpatinib been included in medical insurance reimbursement?

The original drug Selpercatinib has been officially launched in China, providing treatment options for patients with RET gene-positive non-small cell lung cancer (NSCLC), papillary thyroid cancer and other related solid tumors. However, as of now, Seputinib has not been included in China's medical insurance list, so patients still have to pay for it at their own expense when using it in China, which is relatively expensive, which affects the accessibility of the drug to a certain extent. Common specifications in the domestic market are 80mg, 120mg and 160mg tablets. According to the price reference of overseas original drugs, long-term treatment costs are relatively high, especially for advanced patients who require long-term maintenance treatment, the economic burden is significant.

Although it is not included in medical insurance, in domestic clinical practice, some advanced patients still obtain seputinib through regular hospitals or imported drug channels, which is used for RET-positive tumors that cannot be controlled by traditional chemotherapy or multi-target inhibitors. Patients usually need to undergo RET gene testing before use to determine whether it falls within the indication range, so as to achieve precise treatment. With the accumulation of domestic clinical data and the advancement of drug price negotiations, Seputinib is expected to be included in medical insurance in the future, thereby improving the accessibility of more patients, reducing the economic burden, and further expanding the benefits of precision targeted therapy.

In addition, patients need to be closely followed up during use, with regular monitoring of hematology, liver function and cardiovascular indicators. At the same time, attention should be paid to potential adverse reactions, such as hypertension, elevated liver enzymes, diarrhea, etc. Although it is not included in medical insurance, Seputinib has significant clinical efficacy in RET-positive patients and provides an important treatment option for refractory tumors. In the future, medical insurance coverage is expected to improve drug accessibility and patients' long-term treatment experience.

Reference:https://en.wikipedia.org/wiki/Selpercatinib